BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:16:00 PM | Browse: 905 | Download: 878
Publication Name World Journal of Hepatology
Manuscript ID 11877
Country Italy
Received
2014-06-10 08:45
Peer-Review Started
2014-06-10 10:28
To Make the First Decision
2014-07-29 11:53
Return for Revision
2014-08-07 08:25
Revised
2014-08-08 03:06
Second Decision
2014-10-10 18:05
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-10-10 18:20
Articles in Press
2014-10-10 18:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-11-20 09:15
Publish the Manuscript Online
2014-11-20 19:46
ISSN 1948-5182 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis
Manuscript Source Invited Manuscript
All Author List Antonio Facciorusso, Annabianca Amoruso, Viviana Neve, Matteo Antonino, Valentina Del Prete and Michele Barone
Funding Agency and Grant Number
Corresponding Author Michele Barone, Professor, Gastroenterology Section, Department of Medical Sciences, University of Foggia, AOU Ospedali Riuniti, Viale Pinto, 1, 71100 Foggia, Italy. michele.barone@unifg.it
Key Words Cirrhosis; Vaptans; Portal hypertension; Arginin vasopressin; Liver
Core Tip Increasing evidences support the central role of renal function alterations in the pathogenesis of hydroelectrolytic imbalances in cirrhotic patients. Since Arginin Vasopressin (AVP) plays an important role in the development of refractory ascites, dilutional hyponatremia and hepato-renal syndrome, selective antagonists of AVP receptors V2 (vaptans) have been recently introduced in the therapeutic algorithm of advanced cirrhotic patients. Despite the promising results of earlier phase-two studies, randomized controlled trials failed to find significant results in terms of efficacy. Moreover, concerns on their safety profile arise. More robust data from randomized controlled trials are needed.
Publish Date 2014-11-20 19:46
Citation Facciorusso A, Amoruso A, Neve V, Antonino M, Del Prete V, Barone M. Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis. World J Hepatol 2014; 6(11): 793-799
URL http://www.wjgnet.com/1948-5182/full/v6/i11/793.htm
DOI http://dx.doi.org/10.4254/wjh.v6.i11.793
Full Article (PDF) WJH-6-793.pdf
Full Article (Word) WJH-6-793.doc
Manuscript File 11877-Review.doc
Answering Reviewers 11877-Answering reviewers.pdf
Copyright License Agreement 11877-Copyright assignment.pdf
Peer-review Report 11877-Peer review(s).pdf
Scientific Misconduct Check 11877-CrossCheck.jpg
Scientific Editor Work List 11877-Scientific editor work list.pdf